The neutrophil-to-lymphocyte ratio at the prostate-specific antigen nadir predicts the time to castration-resistant prostate cancer

被引：1
|
作者：
Iwamoto, Genta [1 ]
Kawahara, Takashi [1 ,2 ]
Yokomizo, Yumiko [2 ]
Miyoshi, Yasuhide [1 ]
Yao, Masahiro [2 ]
Uemura, Hiroji [2 ]
机构：
[1] Yokohama City Univ, Med Ctr, Dept Urol & Renal Transportat, Yokohama, Kanagawa, Japan
[2] Yokohama City Univ, Grad Sch Med, Dept Urol, Yokohama, Kanagawa, Japan
来源：
ASIAN JOURNAL OF UROLOGY | 2021年 / 8卷 / 03期
关键词：
D O I：
10.1016/j.ajur.2020.05.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：332 / 334
页数：3
相关论文
共 50 条
  • [21] Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
    Teo, Min Yuen
    Morris, Michael J.
    CANCER JOURNAL, 2016, 22 (05): : 347 - 352
  • [22] Editorial Comment to High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy
    van Soest, Robert J.
    INTERNATIONAL JOURNAL OF UROLOGY, 2015, 22 (09) : 834 - 834
  • [23] Survival and Economic Impact of Rapid Prostate-Specific Antigen Doubling Time in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
    Freedland, Stephen J.
    Ramaswamy, Krishnan
    Huang, Ahong
    Sandin, Rickard
    Mardekian, Jack
    Schultz, Neil M.
    Janjan, Nora
    George, Daniel J.
    CLINICAL GENITOURINARY CANCER, 2023, 21 (04) : 419 - 429
  • [24] Neutrophil-to-lymphocyte ratio (NLR) in relation to outcome of castration-resistant prostate cancer (CRPC) patients treated with corticosteroids (CS)
    Mehra, N.
    Lorente, D.
    Jayaram, A.
    Bianchini, D.
    Zafeiriou, Z.
    Kolinsky, M.
    Rescigno, P.
    Mateo, J.
    Thomas, K.
    Dearnaley, D.
    Parker, C.
    De Bono, J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S504 - S504
  • [25] Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer
    Turner, Jeffrey
    Chaudhary, Uzair
    ANTI-CANCER DRUGS, 2009, 20 (03) : 215 - 216
  • [26] Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy
    Tsai, Yuh-Shyan
    Tzai, Tzong-Shin
    UROLOGICAL SCIENCE, 2015, 26 (04) : 277 - 277
  • [27] Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids
    Mehra, Niven
    Sharp, Adam
    Lorente, David
    Dolling, David
    Sumanasuriya, Semini
    Johnson, Bernadette
    Dearnaley, David
    Parker, Chris
    de Bono, Johann
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : 678 - +
  • [28] New prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil to lymphocyte ratio
    Templeton, A. J.
    Pezaro, C.
    Omlin, A. G.
    McNamara, M. G.
    Leibowitz-Amit, R.
    Vera-Badillo, F. E.
    Attard, G.
    De Bono, J. S.
    Tannock, I. F.
    Amir, E.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S684 - S685
  • [29] Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel
    Buttigliero, Consuelo
    Pisano, Chiara
    Tucci, Marcello
    Vignani, Francesca
    Bertaglia, Valentina
    Iaconis, Davide
    Guglielmini, Pamela
    Numico, Gianmauro
    Scagliotti, Giorgio V.
    Di Maio, Massimo
    ACTA ONCOLOGICA, 2017, 56 (04) : 555 - 562
  • [30] Pretreatment Neutrophil-to-Lymphocyte Ratio in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Ketoconazole: Association with Outcome and Predictive Nomogram
    Keizman, Daniel
    Gottfried, Maya
    Ish-Shalom, Maya
    Maimon, Natalie
    Peer, Avivit
    Neumann, Avivit
    Rosenbaum, Eli
    Kovel, Svetlana
    Pili, Roberto
    Sinibaldi, Victoria
    Carducci, Michael A.
    Hammers, Hans
    Eisenberger, Mario A.
    Sella, Avishay
    ONCOLOGIST, 2012, 17 (12): : 1508 - 1514
12345